Description: Ypsomed Holding AG, together with its subsidiaries, develops, manufactures, and sells injection and infusion systems for pharmaceutical and biotechnology companies. The company operates in two segments, Ypsomed Delivery Systems and Ypsomed Diabetes Care. The Ypsomed Delivery Systems segment provides various injection systems, such as pen injectors, auto injectors, patch injectors, and wearable injectors, as well as other smart devices. This segment offers its products under the YDS brand. The Ypsomed Diabetes Care segment sells and trades in insulin pumps, infusion sets, pen needles, blood glucose monitoring systems, accessories, and other day-to-day items for diabetics. This segment offers its products under the mylife brand name. The company offers precision turned parts; and contract manufacturing and other services. It markets its products through biotechnology and pharmaceutical partners, as well as through its own distribution network and independent distributors. It operates in Switzerland, Europe, North America, and internationally. Ypsomed Holding AG was founded in 1984 and is headquartered in Burgdorf, Switzerland.
Home Page: www.ypsomed.com
Brunnmattstrasse 6
Burgdorf,
3401
Switzerland
Phone:
41 34 424 41 11
Officers
| Name | Title |
|---|---|
| Mr. Simon Michel | CEO & Member of the Board |
| Mr. Niklaus Ramseier | Chief Financial Officer |
| Mr. Frank Mengis | COO & Sr. VP of Operations |
| Thomas Kutt | Head of Investor Relations |
| Dr. Beat Maurer | Chief Legal Officer |
| Mr. Michael Zaugg | Chief Corp. Officer |
| Ms. Ulrike Bauer | Chief Bus. Officer |
| Mr. Sebastien Delarive | Chief Bus. Officer |
Exchange: SW
Country: CH
Currency: Swiss Franc (CHF)
| Forward PE: | 37.037 |
|---|---|
| Trailing PE: | 70.3704 |
| Price-to-Book MRQ: | 4.6443 |
| Price-to-Sales TTM: | 4.8483 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 2000 |